Glenmark Life Sciences Ltd. (ALIVUS): Glenmark Life Sciences Share Price Rises 5.67% Today

Glenmark Life Sciences Share Price rises 5.67% to Rs 1,157.6, with a market cap of Rs 13,445.49 crore.

Glenmark Life Sciences Share Price today saw a significant increase, rising by 5.67% to reach Rs 1,157.6. This notable price rise positions the company within the mid cap category, with a market capitalisation of Rs 13,445.49 crore. The stock opened at Rs 1,111.05 and reached a high of Rs 1,166.3 during the trading session. This upward movement in the share price highlights Glenmark Life Sciences as a top gainer in today's market.

< As a mid cap stock, it needed to clear a specific percentage increase to be considered a significant mover, and today's rally has achieved just that. Investors and analysts are keenly observing this development, as it may indicate underlying momentum or interest in the stock.

Glenmark Life Sciences Ltd. (ALIVUS) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,157.6
Previous Close	Rs 1,095.45
Today's Change	+Rs 62.15 (+5.67%)
Day Open	Rs 1,111.05
Day High	Rs 1,166.3
Day Low	Rs 1,111.05
Current Volume (BSE)	12,377
BSE Traded Volume	12,377
NSE Traded Volume	1,19,951
Combined NSE + BSE Volume	1,32,328
Turnover	Rs 1.43 crore
Market Capitalisation	Rs 13,445.49 crore
Market Cap Category	Mid Cap

Glenmark Life Sciences Ltd. (ALIVUS) traded at Rs 1,157.6. versus the previous close of Rs 1,095.45, a rise of 5.67%. The stock opened at Rs 1,111.05, reached Rs 1,166.3, touched Rs 1,111.05. Reported volume was 12,377.

Glenmark Life Sciences Ltd. (ALIVUS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 13,445.49 crore

In the broader context, the Healthcare sector's benchmark P/E median is 25.77, with an average of 94.79, indicating a wide range of valuations within the sector. The P/B median stands at 1.93, with an average of 2.53. These benchmarks provide a comparative framework for assessing Glenmark Life Sciences' valuation relative to its peers.

Investors may consider these fundamental aspects when evaluating the stock's potential for future growth and profitability.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Benchmark Median P/E	25.77x
Benchmark Average P/E	94.79x
Benchmark P/E Range	3.3x to 3,417.8x
Benchmark Median P/B	1.93x
Benchmark Median ROE	10.74%
Benchmark Median ROCE	13.24%
Company Market Capitalisation	Rs 13,445.49 crore
Benchmark Median Market Cap	Rs 140.91 crore

Glenmark Life Sciences Ltd. (ALIVUS) is classified under sector: Healthcare.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

The Healthcare sector, encompassing Pharmaceuticals & Drugs, is a dynamic industry with diverse players. Glenmark Life Sciences operates within this sector, which includes 198 companies. The sector's benchmark P/E median is 25.77, with an average of 94.79, highlighting the variability in valuations across the industry.

Glenmark Life Sciences' market capitalisation of Rs 13,445.49 crore places it among the larger entities within the sector. The benchmark P/B median is 1.93, with an average of 2.53, providing a reference point for evaluating the company's valuation. The sector's ROE median is 10.74%, with an average of 15.09%, while the ROCE median is 13.24%, with an average of 17.57%.

These benchmarks offer insights into the sector's performance and Glenmark Life Sciences' position within it. Investors may use this information to assess the company's competitive standing and potential for growth in the Healthcare industry.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,950.66	0	0.75	-2.89	-0.26
Hikal Ltd.	HIKAL	2,726.18	0	2.23	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,700.98	39.17	7.93	28.21	26.35
Panacea Biotec Ltd.	PANACEABIO	2,598.26	0	8.89	0	5.36
Beta Drugs Ltd.	BETA	2,475.7	58.88	9.32	18.65	22.17

Glenmark Life Sciences Ltd. (ALIVUS) has a market capitalisation of Rs 13,445.49 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Glenmark Life Sciences is compared with several peers in the Healthcare sector, including Dishman Carbogen Amcis Ltd., Hikal Ltd., and Kwality Pharmaceuticals Ltd. These companies vary in market capitalisation, P/E, P/B, ROE, and ROCE metrics.

Dishman Carbogen Amcis Ltd. has a market cap of Rs 2,950.66 crore, with a P/B ratio of 0.75, indicating a lower valuation compared to its peers. Hikal Ltd., with a market cap of Rs 2,726.18 crore, has a P/B ratio of 2.23, reflecting a moderate valuation. Kwality Pharmaceuticals Ltd. stands out with a P/E of 39.17 and a P/B of 7.93, suggesting a higher valuation.

These comparisons provide a framework for evaluating Glenmark Life Sciences' market position and valuation relative to its peers, offering insights into its competitive landscape within the Healthcare sector.

Why Investors Are Watching Glenmark Life Sciences

Investors are closely monitoring Glenmark Life Sciences due to its recent price rise and market position within the Healthcare sector. The company's performance today has drawn attention, prompting further analysis of its potential.

• Significant price rise of 5.67% today.
• Positioned within the mid cap category with a market cap of Rs 13,445.49 crore.
• Operates in the dynamic Healthcare sector.
• Compared with notable peers in the industry.

As Glenmark Life Sciences continues to capture investor interest, monitoring its price action, technical indicators, and sector performance will be crucial for understanding its future trajectory.

About Glenmark Life Sciences

Glenmark Life Sciences Ltd. is a prominent player in the Healthcare sector, focusing on the Pharmaceuticals & Drugs industry. The company is known for its expertise in developing and manufacturing active pharmaceutical ingredients (APIs), catering to a diverse range of therapeutic areas.

With a strong emphasis on research and development, Glenmark Life Sciences aims to deliver high-quality pharmaceutical products to its global clientele. The company's operations are supported by state-of-the-art manufacturing facilities and a commitment to innovation and sustainability.

As a key player in the Healthcare sector, Glenmark Life Sciences continues to expand its product portfolio and strengthen its market presence, contributing to its growth and success in the industry.

Track Glenmark Life Sciences Share Price on Univest

Use Glenmark Life Sciences Ltd. (ALIVUS) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors can track Glenmark Life Sciences Share Price and gain insights into its performance on Univest. The platform provides live share price updates, technical indicators, fundamental ratios, and shareholding patterns, offering a comprehensive view of the stock's market dynamics.

Univest also offers access to 52-week levels and market insights, enabling investors to make informed decisions based on real-time data and analysis.

Frequently Asked Questions

What is the current share price of Glenmark Life Sciences?

Ans. The current share price of Glenmark Life Sciences is Rs 1,157.6, reflecting a 5.67% increase from the previous close. The stock moved 5.67% during the session. The intraday range extended from Rs 1,111.05 to Rs 1,166.3.

How much did Glenmark Life Sciences' share price rise today?

Ans. Glenmark Life Sciences' share price rose by 5.67% today, marking a significant gain for the stock. The stock moved 5.67% during the session. The intraday range extended from Rs 1,111.05 to Rs 1,166.3.

Who are Glenmark Life Sciences' peers?

Ans. Glenmark Life Sciences' peers include Dishman Carbogen Amcis Ltd., Hikal Ltd., and Kwality Pharmaceuticals Ltd., among others. Comparable listed companies include Dishman Carbogen Amcis Ltd., Hikal Ltd., Kwality Pharmaceuticals Ltd.

How does Glenmark Life Sciences' valuation compare to its sector?

Ans. Glenmark Life Sciences' valuation metrics are not specified, but the sector's P/E median is 25.77, and P/B median is 1.93. The relevant peer median P/E is 25.77x. The peer average P/E is 94.79x.

What is the benchmark P/E for the Healthcare sector?

Ans. The benchmark P/E median for the Healthcare sector is 25.77, with an average of 94.79, indicating a wide range of valuations. The relevant peer median P/E is 25.77x. The peer average P/E is 94.79x.